NEW YORK (Reuters Health) - Pfizer's blockbuster antihistamine Zyrtec has gained a supplemental US approval for use in children as young as 6 months old, the US Food and Drug Administration (news - web sites) (FDA) said Tuesday.
Zyrtec (cetirizine hydrochloride)--which is currently indicated to relieve symptoms of allergic rhinitis, or nasal inflammation, and to treat itching and hives in adults and in children age 2 and older--has now been cleared for those two indications in children 6 months and older, Pfizer confirmed.
ALL INFORMATION, DATA, AND
MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION
PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS
OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR
LEGAL ADVICE. THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND
COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH
YOUR HEALTH CARE PROVIDER.